Expanded Access to investigational drugs presents strategic, regulatory, and operational challenges for sponsors supporting patients with serious or life-threatening conditions.
As FDA expectations evolve, sponsors must balance patient-centric access with scientific integrity, trial continuity, and strict compliance with Section 561A and IND regulations. The approach is shifting from ad-hoc compassionate use decisions to a disciplined, strategy-driven Expanded Access framework aligned with regulatory readiness and long-term development goals.
Read our guide to explore more about:
- How FDA Expanded Access criteria and pathways apply to your development program
- How to navigate individual patient, intermediate-size, and Treatment IND access
- What regulatory, operational, and safety responsibilities sponsors must fulfill
- How a structured Expanded Access strategy supports compliance, trust, and approval readiness